The results of a new MDF-funded study on the impact of congenital myotonic dystrophy are now available from Dr. Nicholas Johnson of the University of Utah and colleagues. The high frequency of social and cognitive issues in their findings underline the need for a multi-disciplinary approach to care.
Many common DM symptoms become more severe during pregnancy, and women with DM have higher than average miscarriage rates, according to a study commissioned by MDF that examined data from the Myotonic Dystrophy Family Registry and the National Registry for DM and FSHD. Read a summary of the findings written by Katharine Hagerman, PhD, Research Assistant at Stanford University.
The use of anesthesia raises special risks to DM patients, which include heightened sensitivity to sedatives and analgesics. Serious complications are most common in the post-anesthesia period when risk of aspiration and other complications are increased.
MDF has published two versions of its 2016 Anesthesia Guidelines:
- Click here for a handy, one-page summary of the anesthesia guidelines to share with your clinician and anesthesiologist.
- Click here for the complete "Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient".
New to DM? For here for more information.
Word came from the FDA on January 14th that it would not approve the new drug application for "Kendrisa," Biomarin's antisense-oligo based drug for Duchenne muscular dystrophy.
Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.